Core Insights - BioHarvest Sciences Inc. will host a Virtual Investor Webinar on September 10, 2025, at 1:00 PM ET to provide updates on corporate initiatives and future plans [1][2] - CEO Ilan Sobel will discuss new capability-building initiatives and the company's 'Big Bets' for the second half of 2025, including the Health Pros program and hydration products [2] - The webinar will include a question-and-answer session for participants, emphasizing the company's focus on profitable growth and long-term shareholder value [2] Company Overview - BioHarvest Sciences Inc. is a leader in Botanical Synthesis, utilizing patented technology to grow active ingredients in plants without cultivating the plants themselves [4] - The company operates in two main business verticals: as a contract development and production organization (CDMO) for complex molecules and as a creator of proprietary nutraceutical health and wellness products [4] - BioHarvest aims to develop science-based and clinically proven therapeutic solutions, enhancing its product offerings and expanding its CDMO pipeline [4]

Core Insights - BioHarvest Sciences Inc. has successfully progressed its CDMO contract with a Nasdaq-listed pharmaceutical company from Stage 1 to Stage 2, validating its Botanical Synthesis platform for developing active pharmaceutical compounds [1][4] Group 1: Contract Development and Manufacturing Organization (CDMO) Progress - Stage 1 of the contract, initiated in early 2024, involved sourcing plants to develop a compound for an approved drug product, which has now been completed successfully [2] - The successful completion of Stage 1 indicates that the research team isolated and multiplied the target plant cells using the proprietary Botanical Synthesis platform [2] - Stage 2 will focus on delivering sufficient biomass for testing and developing optimal growing conditions, leading to small and medium-scale production and eventually commercial volume production [3] Group 2: Company Statements and Future Outlook - The CEO of BioHarvest expressed excitement about advancing to Stage 2, highlighting the milestone as a validation of the platform's versatility and its potential to provide cost-effective alternatives to traditional sourcing methods [4] - The Chairman of the CDMO Division noted that Stage 1 carried the highest technical risk, and its successful completion demonstrates the platform's capability to address a wide range of molecule families, with Stage 2 expected to have a higher probability of success [4]